PT-141, also known as bremelanotide, is a synthetic cyclic melanocortin peptide supplied as a lyophilised research material for controlled studies of melanocortin-receptor pharmacology, ligand binding, GPCR signalling and peptide structure–activity relationships.
Research material only
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
Research context
PT-141 is the research code historically used for bremelanotide, a cyclic peptide derived from melanocortin peptide-design work. Its lactam-constrained structure contains norleucine and D-phenylalanine residues and has been studied as a ligand at melanocortin receptors, including MC3R and MC4R.
Published work includes receptor-pharmacology studies, animal models, structural investigation of bremelanotide bound to MC4R, and human clinical research performed with defined pharmaceutical preparations. These sources provide compound-level context only and do not establish the identity, performance or suitability of the material supplied on this page.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the vial size and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied in the vial size selected above.
- Provided as a lyophilised material for laboratory research.
- Use calibrated equipment and an independently validated protocol appropriate to the intended study.
- Record the product designation, vial size, batch identifier and preparation conditions in the laboratory record.
Frequently asked questions
What is PT-141?
PT-141 is the historical research code for bremelanotide, a synthetic cyclic melanocortin peptide.
Is PT-141 the same designation as bremelanotide?
Yes. PT-141 was the investigational code used for the compound now known as bremelanotide. The applicable product and batch documentation should still be used to confirm the identity of a supplied material.
Why is PT-141 described as a cyclic peptide?
The reference structure contains a lactam ring linking side-chain functional groups within the peptide, constraining its conformation compared with a corresponding linear chain.
What research is linked on this page?
The Research tab links to compound-identification data and published receptor-pharmacology, structural, animal-model and clinical studies. These sources provide scientific context and are not product-performance claims.
Which vial sizes are available?
Current vial sizes and availability are shown in the size selector above. This information updates with the product variations rather than being fixed in the description.
Are published laboratory results available?
Where a published batch record exists, a result indicator appears beside the applicable variation and the corresponding documentation is available on the lab-results page. No indicator means that no product-specific published result is currently displayed for that variation.
How should PT-141 be stored?
Protect sealed lyophilised vials from light, moisture and repeated temperature changes. After reconstitution, store the reconstituted solution refrigerated at 2–8°C and follow a validated laboratory protocol for handling and use.
Information reviewed 29 August 2026.
